PHRM3012 2017 Questions by karlwinckel

CAP v IE COPd

karlwinckel — 2017-10-13 04:37:59 UTC

Hi Karl, What is the difference between these.

evidence example results

2017-10-16 10:02:16 UTC

hi karl. when can we know our results for the evidence examples? and will we be getting feedback for them? thanks

C.A. meningitis

2017-10-16 10:02:56 UTC

It says that "carriage of N. meningitidis may be protective (antibodies)." May I know what does that mean? thanks.

For the vaccination, does the childhood schedule 12 months means every 12 months?

SSTI

2017-10-16 11:02:31 UTC

slide 17: if there is a wide range of causative pathogens, why is microbiological evidence less useful? wouldn't that be more specific?

foodborne illness

2017-10-18 23:54:41 UTC

how do you differentiate between the type of illnesses? for example, typhoid fever or traveller diarrhea

Child dose

2017-10-19 03:04:17 UTC

Hi Karl. I noticed a few dose calculations in lecture slides for protozoa ones - metronidazole and cotrimoxazole. Will we be given with the child doses in exam? or do we have to memorise 30mg/kg for metronidazole and 5/25mg/kg for cotrimoxazole? What about the available strengths for different forms of cotrimoxazole? Thanks!

Oral Exam

2017-10-19 03:31:24 UTC

Hi Karl, For the Category 1 drugs which will be assessed in the oral exam do we need to know all the bacteria which they are sensitive to or is it sufficient enough to know that they have gram-negative and/or gram-positive cover? Thanks!

Oral exam station 2

2017-10-20 07:35:30 UTC

Will the scenario given be more of a common indication or will it be a less common one?

Bacterial meningitis

2017-10-20 07:56:51 UTC

for the emperical therapy of bacterial meningitis: in the lecture note states Ceftriaxone 2 g stat. But in AMH the dose of ceftriaxone for bacterial meningitis is 1-2g every 12 hours. In eTG, the dose of ceftriaxone is 4g IV daily or 2g 12-hourly.
Which is the dose that we should use?
Based on eTG, there is different treatment regime for different type of species. What would you expect us to know? Or empirical therapy is enough?

Chemo Lectures

2017-10-20 09:50:13 UTC

Should we be learning each individual drug name or just learn the classes and understand their use in therapy? Should we additionally learn their MOAs in depth?

Oral exam station 1

2017-10-21 00:05:34 UTC

Hi Karl. Once we enter the mock pharmacy room, do we straightaway ask the prescriber whether we can pretend that the device is a placebo? and we have to clarify to the patient that "this is a demo device that we have and yours will look exactly like this too." ?

Opioid Dose Conversions

2017-10-21 05:04:01 UTC

Will we be required to calculate opioid dose conversions for the exam? If so, will we be given conversion factors?

Syringe Driver Compatibility

2017-10-21 05:05:03 UTC

With regards to Sophie's Palliative care lecture, she had a slide (36) with a table of different drugs and their compatibility within syringe drivers. Will we be required to know this for the exam?

resp

2017-10-22 00:06:31 UTC

tawhat's the difference between hyperreactivity and hypersensitivity?

Stepwise Management of stable COPD

2017-10-22 00:52:55 UTC

For the short-acting reliever medication, may I know that in what situation we will give SAMA instead of SABA?

Also, if the patient is using SABA as the reliever medication, which combination (LAMA only; LABA only) is preferred to be added on first? Is there a certain rule in choosing any add-on combination (perhaps under certain situation)?

If the patient is on SABA and LABA, and have fulfilled the two conditions for using an ICS, should we just give ICS straight away or we can try to add on the LAMA first instead of ICS?

Puffer Vs. Nebuliser

2017-10-22 01:24:11 UTC

Other than acute exacerbation of asthma and COPD, is there any other situation that we give salbutamol nebules to the patient instead of puffer?

Dispensing 2 worksheet

2017-10-22 01:29:33 UTC

There is a question asking about how the Bricanyl inhaler is different to the Ventolin inhaler. When we explaining that, should we discuss with the patient about whether it is a DPI or MDI device? Also, would that be enough that we just discuss about how different are the ways of using these two devices? Should we include their advantages over each other in the discussion?

Risk Factors

2017-10-22 11:30:44 UTC

Hi Karl, When reading the asthma management guidelines it goes into alot of detail about risk factors, signs of exacerbation, poor management etc...Are we expected to know/memorise this information which is presented in the guidelines? Or, is it more important to understand the concepts and key ideas? Thanks!

TB

2017-10-22 12:22:18 UTC

hi karl, in slide 57, why would timely and affordable access to medications lead to difficulty in systematic supply of medications? thanks!

Bacterial rhinosinusitis

2017-10-22 23:03:35 UTC

For the treatment using amoxycillin and clavulanic acid, u stated that we should counsel on the repeats in the lecture note. Can you go through this and give us an example so we can have an idea on how should we counsel on this?

COPD

2017-10-22 23:07:02 UTC

In the COPD management lecture, there are a few slides on the different evidence levels. Do we need to know the different levels of eveidence by hard?

Asthma management lecture 2

2017-10-22 23:12:21 UTC

In slide 11, the first dot point stated that increase the risk of patient requirement for antibiotics. Can you explain on this? Why the patients need antibiotics in this case?

Asthma management 2

2017-10-22 23:14:42 UTC

On slide 20, it stated that breezhaler can be washed every month or so. Is this statement correct? Because i thought only the mouthpiece can be cleaned but the inhaler itself cannot be washed with water.

Skin and soft tissue infections lecture

2017-10-22 23:17:48 UTC

For the example case MR VM and Mr PG, the empiric therapy is flucloxacillin 500mg TDS po. However, when i look into amh and eTG, it is dosed on every SIX hours. So wouldn't it be QID instead of TDS?

Inflenza lecture

2017-10-22 23:20:37 UTC

On slide 49, it is stated that treatment should be given for at risk groups and all hospitalised patients. Is this prophylaxis instead of treatment? Because those people haven't actually get the disease and this is just to prevent them from getting the disease?

Cancer lectorial

2017-10-23 00:04:28 UTC

Case 2
For the short acting filgrastim, i understand that the patient needs the short acting one because his chemotherapy is due and we might dont want to delay his chemotherapy for too long period and want to recover him from neutropenia as soon as possible. But i didnt quite understand regarding the pegfilgrastim for every subsequent cycle of chemotherapy. Is it we have to give pegfilgrastim for every patient that has neutropenia during previous chemotherapy?

Dose

2017-10-23 03:48:00 UTC

I know we should memorize the dose for each antimicrobial for station 2, but do we also need to memorize IV/IM dose and the dose for child/neonate?

Station 2

2017-10-23 11:55:06 UTC

Are we going to be given the drug name(s) OR the brand name OR both?

Questions In Station 2

2017-10-23 11:57:52 UTC

After reading the information sheet provided about oral exam, I have found that the possible questions in station 2 are around the dose and spectrum of the drug, appropriateness of the drug for the condition (i.e. if it is first line Tx) and other drugs that are appropriate to treat the condition. Is there any other areas that we can focus on to shape our preparation for the oral exam? For instance, do we have to know the common side effects of the drug and what side effects may require the patient to seek medical attention, the possible drug interactions and common counselling points for the drug such as if it is to be taken with food or not? It would be highly appreciated if a list could be provided as to what areas of questions are we expecting.

Cases for Written Exam

2017-10-23 12:02:54 UTC

What information from the cases should I study to prepare for the exam?
How many questions can I expect in the exam from the assignment cases?

Doses for Written Exam

2017-10-23 12:04:06 UTC

Do we have to know the doses of ALL the medications covered in the lecture?
Do we have to know the initial and maintenance doses and when should dose be reduced/increased?

Drugs for Exam

2017-10-23 12:05:28 UTC

Are we required to know all the drugs in the lectures? For a condition, do we have to know the first line therapy, second line therapy and so forth?
Do we have to know all the side effects for all drugs?
Do we also have to know when will a monitoring be required for ALL the drugs?

SAQ

2017-10-23 12:07:46 UTC

What can we expect in the SAQ and how can we prepare for it?
What is the structure of the SAQs? Is it possible for you (Mr Karl) to provide us some sample answers to the SAQs? It will give us clear ideas as to how you expect us to answer the SAQs.

Station 1

2017-10-23 12:12:37 UTC

Will the correct dose of the drug in station 1 be written on the prescription?
Do we need to take a calculator with us? Will we be required to calculate doses?
Are resources available in the perusal time AND also in the counselling part of Station 1?

Oral exam docs

2017-10-24 00:12:27 UTC

Based on the oral exam docs that you posted, question on amoxycillin spectrum of activity, it is stated that amoxicillin has good gram +ve cover including staph aureus. But based on AMH susceptibility table, amoxycillin is not active against Staph aureus. Could you explain this?

inhalers doses

2017-10-24 00:33:03 UTC

the doses have not been covered in the lectures. do we have to know the exact doses for all inhalers medications? i notice that sample exam paper does need us to know all inhaler doses? I'm confused with what else we are suppose to know if they are not covered in the lectures. are lecture notes sufficient for the exam? to what extent do we have to know outside the lecture slides?

Amoxycillin/clavulanic acid oral docs

2017-10-24 01:44:28 UTC

In the oral docs that you had posted, it stated dose should be reduced for renal impairment for amoxycillin/clavulanic acid. In AMH stated "Reduce IV dose if CrCl <30 mL/minute".

The question is during oral exam, do we need to specify "only IV route need dose reduction and oral route does not require dose reduction" OR saying dose reduction require for renal impairment is sufficient??

Samples for Oral

2017-10-24 02:08:46 UTC

Can you provide sample videos of the interactions for both Station 1 and 2?

Station 2

2017-10-24 02:15:52 UTC

Do we initiate the interaction?

Statistic in lectures

2017-10-24 02:22:29 UTC

There are some statistics in the lecture about population (i.e. percentage of people affected by a disease) and etc. Do we have to know them?

Beyond Lecture contents

2017-10-24 02:23:41 UTC

Are we required to know details about conditions/treatments that are not covered in the lecture but are present in the our common resources (AMH, eTG)?